Loading clinical trials...
Loading clinical trials...
Phase II/III of Randomized Controlled Clinical Research on Irreversible Electroporation Synchronous Chemotherapy for Locally Advanced Pancreatic Adenocarcinoma
Conditions
Interventions
Irreversible electroporation
Gemcitabine
Locations
1
China
Institutional Review Board of Guangzhou FUDA Cancer Hospital
Guangzhou, Guangdong, China
Start Date
September 1, 2019
Primary Completion Date
June 30, 2021
Completion Date
July 30, 2021
Last Updated
September 5, 2021
NCT06998940
NCT06381154
NCT05825066
NCT05679674
NCT07241663
NCT04665947
Lead Sponsor
Fuda Cancer Hospital, Guangzhou
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions